Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T19:13:06.664Z.
Calculation as of: 2026-10-06T19:13:06.664Z.
Quote observation: 2026-10-06T18:42:37.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f7eba9f13d95fb6821c25c67f521ed103bec1ea18c2b869fb2c3b9acf85efa0e
PE RATIO
N/A
Passage Bio, Inc.
Market Cap
$13.08M
PE Ratio
N/A
| NAME | MARKET CAP | PE RATIO |
|---|---|---|
| Passage Bio, Inc. (PASG) | $13.08M | N/A |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $13.22M | N/A |
| IN8bio, Inc. (INAB)vs › | $13.33M | N/A |
| Optimi Health Corp. (OPTH)vs › | $13.61M | N/A |
| Cytosorbents Corporation (CTSO)vs › | $12.77M | N/A |
| Dare Bioscience, Inc. (DARE)vs › | $12.51M | N/A |
| Lantern Pharma Inc. (LTRN)vs › | $12.41M | N/A |
| Tempest Therapeutics, Inc. (TPST)vs › | $12.43M | N/A |
| Cellectar Biosciences, Inc. (CLRB)vs › | $12.38M | N/A |
| Obsidian Therapeutics Inc. (OBX)vs › | $13.81M | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$4.07
Forward EPS (Est.)
$-9.78
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
